{
  "symbol": "MRK",
  "year": 2022,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2135,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.072
  },
  "top_positive": [
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    },
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    },
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    }
  ],
  "top_negative": [
    {
      "sent": "Phase 2 Cancer MK-0482 (3) Non-Small-Cell Lung MK-1026 (nemtabrutinib) Hematological Malignancies MK-1200 Neoplasm Malignant MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Advanced Solid Tumors Colorectal Hepatocellular Melanoma Small-Cell Lung MK-2140 (zilovertamab vedotin) Breast Gastric Hematological Malignancies Non-Small-Cell Lung Ovarian Pancreatic Solid Tumors MK-2870 (1)(3) Neoplasm Malignant MK-3475 Keytruda Advanced Solid Tumors MK-4280 (favezelimab) (2) Hematological Malignancies Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Renal Cell Small-Cell Lung MK-4830 (2) Colorectal Melanoma Non-Small-Cell Lung Renal Cell Small-Cell Lung MK-5684 (1) Neoplasm Malignant MK-5890 (3) Non-Small-Cell Lung Small-Cell Lung Cancer MK-6440 (ladiratuzumab vedotin) (1)(3) Breast Esophageal Gastric Head and Neck Melanoma Non-Small-Cell Lung Prostate Small-Cell Lung MK-6482 Welireg (3) Biliary Colorectal Hepatocellular Pancreatic Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU) MK-7119 Tukysa (1) Advanced Solid Tumors Biliary Bladder Cervical Colorectal Endometrial Gastric Non-Small-Cell Lung MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684 (vibostolimab) (2) Melanoma MK-7684A (vibostolimab+pembrolizumab) Biliary Breast Cervical Colorectal Endometrial Esophageal Head and Neck Hematological Malignancies Hepatocellular Prostate Cancer MK-7902 Lenvima (1)(2) Biliary Glioblastoma Pancreatic Prostate Small-Cell Lung V937 Breast Cutaneous Squamous Cell Head and Neck Melanoma Solid Tumors Cardiovascular MK-2060 Chikungunya Virus Vaccine V184 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(4) Hypercholesterolemia MK-0616 Nonalcoholic Steatohepatitis (NASH) MK-3655 MK-6024 Overgrowth Syndrome MK-7075 (miransertib) Pulmonary Arterial Hypertension MK-5475 Schizophrenia MK-8189 Treatment Resistant Depression MK-1942 - 46 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(5) Cancer MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-3475 Keytruda Biliary (September 2019) Cutaneous Squamous Cell (August 2019) (EU) Gastric (May 2015) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Prostate (May 2019) Small-Cell Lung (May 2017) MK-3475 (pembrolizumab subcutaneous) Non-Small-Cell Lung (August 2021) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) MK-6482 Welireg (3) Renal Cell (February 2020) MK-7119 Tukysa (1) Breast (October 2019) MK-7339 Lynparza (1)(3) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Colorectal (April 2021) Esophageal (July 2021) Gastric (December 2020) Head and Neck (February 2020) Melanoma (March 2019) Non-Small-Cell Lung (March 2019) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (4) HIV-1 Prevention MK-8591 (islatravir) (February 2021) (4) Pneumococcal Vaccine Adult V116 (July 2022) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) New Molecular Entities/Vaccines Antiviral COVID-19 MK-4482 Lagevrio (EU) (1) Cough MK-7264 (gefapixant) (U.S.) (6) (EU) Pneumococcal Vaccine Adult/Pediatric V114 (JPN) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Second-Line Hepatocellular Cancer (KEYNOTE-394) (U.S.) \u2022    Adjuvent Non-Small-Cell Lung Cancer (KEYNOTE-091) (U.S.) (EU) \u2022    High-Risk Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) (JPN) \u2022    Cervical Cancer (KEYNOTE-826) (JPN) \u2022    Adjuvent Renal Cell Cancer (KEYNOTE-564) (JPN) MK-7339 Lynparza (1) \u2022 BRCA -Mutated HER2-Negative Adjuvant Breast Cancer (OlympiA) (JPN) \u2022    First-Line Metastatic Prostate Cancer (PROpel) (EU) (JPN) MK-7902 Lenvima (1)(2) \u2022    First-Line Metastatic Hepatocellular Carcinoma (KEYNOTE-524) (U.S.) (7) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.9939
    },
    {
      "sent": "There have been no material changes to the risk factors as previously disclosed in the Company\u2019s Annual Report on Form 10-K, except as follows: The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company\u2019s business, results of operations and financial condition.",
      "score": -0.886
    },
    {
      "sent": "However, the degree to which the war and related disruptions will impact the Company\u2019s results for the remainder of 2022 or beyond is difficult to predict and will depend on developments outside of the Company\u2019s control, including, but not limited to, the duration and severity of the conflict, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets.",
      "score": -0.7846
    }
  ],
  "forward_snippets": [
    "Merck\u2019s existing research pipeline programs continue to be owned and developed within Merck as planned.",
    "Recently Adopted Accounting Standards In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity\u2019s own equity.",
    "The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments.",
    "The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach.",
    "In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy."
  ]
}